se gb

Lena Wikingsson new CEO of Dilafor

STOCKHOLM, May 16, 2011. Lena Wikingsson has been appointed CEO of Dilafor AB. She has several years of experience from pharmaceutical development in leading positions within the pharmaceutical industry. She has, among others, been assessor of biotechnology products at the Swedish Medical Products Agency and CEO of Independent Pharmaceutica.

Beng Å Johansson, Chairman of the Board, Dilafor:
"Dilafor has successfully completed a Phase IIa-program for the treatment of protracted labor. We are currently planning a Phase IIb-program which we expect to carry through during 2012. In the light of these events we are very delighted with the recruitment of Lena Wikingsson. She has broad experience from pharmaceutical development, both in the clinical and regulatory setting, which is of great importance at this key stage for the company."

Lena Wikingsson, newly appointed CEO, Dilafor:
"Tafoxiparin has the opportunity to fill an unmet medical need at protracted, and therefore difficult, labor. It is of great importance, both for mother and child, that the time of delivery can be reduced as protracted labors increases the risk of medical complications. I am looking forward to bring this project into the next clinical development phase and create the foundation for making it a commercial success."

For more information, please contact:
Bengt Å Johansson, Chairman of the Board, Dilafor AB
Phone: +46 (0)706 804 762, e-mail: bengt.johansson@dilafor.com

Lena Wikingsson, CEO, Dilafor AB
Phone: +46 (0)707 900 207, e-mail: lena.wikingsson@dilafor.com

TO THE EDITORS

About Dilafor
Dilafor develops tafoxiparin, a candidate drug for preventing and treating protracted labor and thereby decreasing the risk for complications for both mother and child. Based on clinical observations that indicate that protracted labors can be normalized by low molecular weight heparin (LMWH), Dilafor has developed tafoxiparin. LMWH is normally used for the prevention of thrombosis (blood clots), an effect that could cause an increased risk hemorrhage at childbirth. A tailor made compound, tafoxiparin, has been developed by selective modification of LMWH with the purpose of eliminating the anticoagulative properties. In both preclinical and clinical studies the compound has been proven to be safe. Dilafor has successfully completed an explorative clinical Phase II trial of tafoxiparin in protracted labor. www.dilafor.se

pdf.png Lena Wikingsson new CEO of Dilafor

2011-05-16